Rebecca B Riggins

Has grant

Professor

Georgetown University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Dynamic Precision Medicine for Drug Resistant HER2+/ER+ Breast Cancer

Open Date: 2025-01-01

Close Date: 2026-12-31

Grant: Open

Novel functions of ESRRB in glioblastoma

Open Date: 2024-02-08

Close Date: 2029-01-31

Grant: Close

Georgetown University ACS DICR Program

Open Date: 2024-01-01

Close Date: 2025-12-30

Grant: Open

Institutional Research Grant

Open Date: 2024-01-01

Close Date: 2026-12-31

Grant: Close

Diversity in Cancer Research Supplement: Georgetown University

Open Date: 2023-05-01

Close Date: 2024-04-30

Articles (25)

Year:

2025

Year:

2025

Year:

2025

PURPOSE Current precision medicine (CPM) matches patients to therapies using traditional biomarkers, but inevitably resistance develops. Dynamic precision medicine (DPM) is a new evolutionary guided precision medicine (EGPM) approach undergoing translational development. It tracks intratumoral genetic heterogeneity and evolutionary dynamics, adapts as frequently as every 6 weeks, plans proactively for future resistance development, and incorporates multiple therapeutic agents. Simulations indicated DPM can significantly improve long-term survival and cure rates in a cohort of 3 million virtual patients representing a variety of clinical scenarios. Given the cost and invasiveness of monitoring subclones frequently, we sought to determine the value of a short DPM window of only two 6-week adaptations (moves). METHODS In a new simulation, nearly 3 million virtual patients, differing in DPM input parameters of initial subclone compositions, drug sensitivities, and growth and mutational kinetics, were simulated as previously described. Each virtual patient was treated with CPM, DPM, and DPM for two moves followed by CPM. RESULTS The first two DPM moves provide similar average benefit to a 5-year, 40-move sequence in the full virtual population. If the first two moves are identical for DPM and CPM, patients will not benefit from DPM (65% negative predictive value). A patient subset (20%) in which 2-move DPM and 40-move DPM provide closely similar outcomes has extraordinary predicted benefit (hazard ratio of DPM/CPM 0.03). CONCLUSION The first two DPM moves provide most of the clinical benefit of DPM, reducing the duration required for subclone monitoring. This also leads to an evolutionary classifier selecting patients who will benefit: those in whom DPM and CPM recommendations differ early. These advances bring DPM (and potentially other EGPM approaches) closer to potential clinical testing.

Year:

2025

Despite advances in targeted cancer therapy, the promise of precision medicine has been limited by resistance to these treatments. In this study, we propose a mathematical modelling framework incorporating cellular heterogeneity, genetic evolutionary dynamics, and non-genetic plasticity, accounting for both irreversible and reversible drug resistance. Previously we proposed Dynamic Precision Medicine (DPM), a personalized treatment strategy that designed individualized treatment sequences by simulations of irreversible genetic evolutionary dynamics in a heterogeneous tumor. Here we apply DPM to the joint model of reversible and irreversible drug resistance mechanisms, analyze the simulation results and compare the efficacy of various treatment strategies. The results indicate that this enhanced version of DPM results in superior patient outcomes compared with current personalized medicine treatment approaches. Our results provide insights into cancer treatment strategies for heterogeneous tumors with genetic evolutionary dynamics and non-genetic cellular plasticity, potentially leading to improvements in survival time for cancer patients.

Year:

2024

Invasive Lobular Carcinoma (ILC) is a subtype of breast cancer characterized by distinct biological features, and limited glucose uptake coupled with increased reliance on amino acid and lipid metabolism. Our prior studies highlight the importance of glutamate as a key regulator of ILC tumor growth and therapeutic response. Here we examine the expression of four key proteins involved in glutamate transport and metabolism – SLC3A2, SLC7A11, GPX4, and GLUD1/2 – in a racially diverse cohort of 72 estrogen receptor-positive (ER+) ILC and 50 ER+ invasive ductal carcinoma, no special type (IDC/NST) patients with primary disease. All four proteins associate with increased tumor size in ILC, with three showing stronger associations in Black women, but not in IDC/NST. Among these three proteins in ILC, GLUD1/2 uniquely associates with ER expression in all women, while GLUD1/2 and SLC3A2 are enriched in hypertensive women. GLUD1/2 and GPX4 are upregulated in endocrine therapy-resistant ILC cell lines, and pharmacological inhibition of GLUD1 reduces ER protein levels and cell viability. Together, these findings support a potentially important role for glutamate metabolism in ILC and suggest GLUD1 and other glutamate-handling proteins as candidate targets for therapeutic intervention in ILC.

Year:

2024

WNT4 variant genotype is associated with active WNT4 signaling and metabolic remodeling in ovarian cancer cells. A, Left, Proliferation assessed by dsDNA quantification 6 days post-transfection with siRNA (siNT = non-targeting control pool). Bars represent mean of 6 biological replicates ± SD; *, P t test with Welch correction. WT versus Var model comparison by t test of mean fold changes for siWNT4 versus siNT. Right, WNT4 mRNA by qPCR in parallel samples, 72 hours after siRNA. Mean of biological triplicate, fold change versus siNT. B, Lysates harvested 72 hours posttransfection. MCL1 levels assessed by densitometry and normalized to total S6 loading control (6). Fold change in normalized MCL1 levels in Variant versus WT genotype cell lines compared by Student t test. C, Metabolites dysregulated 72 hours after WNT4 knockdown ( n = 44), as for MM134. D, Fold changes in lipid metabolites. Dashed line on y -axis: FDR = 0.2. E, Pathway enrichment (Metaboanalyst) for metabolites shown in C; K = KEGG, S = SMPDB.

Year:

2024

WNT4 overexpression rescues some metabolic effects of ER:WNT4 pathway inhibition. A, Small-molecule inhibitor targets in current model of ER:WNT4 signaling pathway. B, Meta-analysis of parental MM134 cells versus WNT4-OE MM134 across drug treatment series (i.e., WNT4 effect controlled for inhibitor effect) identifies n = 71 metabolite levels altered by WNT4 overexpression. Green = overlap with siWNT4 dysregulated metabolites. C, Overall changes in metabolite levels caused by WNT4 knockdown versus WNT4 overexpression are inversely correlated, supporting regulation of associated metabolic pathways by WNT4. D, Inhibitor effects in parental MM134 versus WNT4-OE MM134 are strongly correlated, but a subset of inhibitor effects are reversed by WNT4 overexpression. E, Metabolites for which inhibitor effects is decreased by ≥30% for at least two inhibitors ( n = 39).

Year:

2024

Metabolic effects of WNT4 knockdown mirror ER knockdown but have expanded impact on fatty acid and amino acid metabolic pathways. A, Metabolite levels altered by WNT4 knockdown ( n = 77); pink text indicates a shared affected metabolite with ER knockdown. B, Metabolites dysregulated by WNT4 versus ER knockdown are strongly enriched for overlap. C, WNT4 versus ER knockdown effects on metabolite levels are strongly directly correlated, suggesting an overall parallel effect on ILC cell metabolism. D, Pathway analysis with ER metabolites (C) and WNT4 metabolites ( Fig. 4A ); P

Year:

2024

BioID supports WNT4 localization to the mitochondria. A, Proteins enriched in HT1080 Wnt-BirA versus parental HT1080 cells lacking BirA construct expression. B, Overlap of proteins identified in HT1080 (A) versus HT1080-PKO and MM134 identifies n = 72 “high-confidence” WNT4-associated proteins. C, Gene ontology analysis for cellular compartment for WNT3A- versus WNT4-associated proteins. Dashed line = 1.3 ( P = 0.05). D, Network analysis of WNT3A- versus WNT4-associated proteins via subcell barcode. Enrichments against cell line HCC287 background shown; parallel results observed with other cell line background data, for example, MCF7. E, Proteins with predicted cytosolic or mitochondrial localization (subcell barcode) among “high-confidence” WNT4-associated proteins. Red = predicted mitochondrial localization, pink = mTOR complex in mitochondrial dynamics, biogenesis, and autophagy. F, Biotin treatment and streptavidin pulldown was performed as for MS studies, and candidate WNT4-associated proteins from E detected by immunoblotting. Total protein by Ponceau.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (11)

Jesus Tejero

University of Pittsburgh

UNITED STATES
View details

Madeleine Shackleford

Professional Research Assistant

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Erik Nelson

Professor

University of Illinois at Urbana-Champaign

UNITED STATES
View details

Junxiao Hu

Assistant Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Benjamin Bitler

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Matthew Sikora

Associate Professor

University of Denver

UNITED STATES
View details

Shaymaa Bahnassy

Assistant Professor

Georgetown University

UNITED STATES
View details

Steffi Oesterreich

UPMC Hillman Cancer Center

UNITED STATES
View details

Linda Cook

Professor

University of Colorado Cancer Center

UNITED STATES
View details

Suman Ranjit

Assistant Professor

Georgetown University

UNITED STATES
View details

Zeynep Madak-Erdogan

Professor

University of Illinois at Urbana-Champaign

UNITED STATES
View details